Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

Summary

The purpose of this research study is to gather information on the effectiveness and tolerability of a novel composition of existing U.S. Food and Drug Administration (FDA) approved topical medications for the treatment of moderate to severe melasma.

Timeline

Start

2016-05-15

Primary completion

2016-12-30

Completion

2016-12-30

Drugs

Indications